Published in Drug Law Weekly, September 4th, 2007
CT-322 is an Adnectin that was designed to be both a potent and highly specific antagonist of the vascular endothelial growth factor receptor 2 (VEGFR-2). VEGFR-2 activation is believed to be the primary driver of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.